Extract

To explore the efficacy of vemurafenib as a single agent across diverse type of tumors guided by the presence of identified activating molecular alterations in the vemurafenib target gene, per cohort.

Inclusion criteria

• Patient with BRAF V600 mutation determined on the primary and/or metastatic lesion in the following pathologies:
• . NSCLC
• . Ovarian cancer
• . Cholangiocarcinoma
• . Thyroid cancer
• . Prostatic cancer
• . Bladder cancer
• . Sarcoma/GIST
• . Multiple myeloma
• . Chronic Lymphocytic Leukemia (CLL)
• . Hairy cell leukaemia (HCL) (this excludes Hairy Cell Leukemia variant types, marginal zone splenic lymphoma (MZL), splenic red pulp lymphoma (SRPL) patients)

Links

• ictrp
• euctr